Showing results (161-170 of 181) with videos related to

Sort By:
Pageof 19
JAMA|June 5, 2007
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancerPardeep Kaurah, Andrée MacMillan, Niki Boyd, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
VISTA-induced tumor suppression by a four amino acid intracellular motifYan Zhao, Tina Andoh, Fatima Charles, et al.
Cancer Research|July 14, 2025
A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor SuppressionYan Zhao, Tina Andoh, Fatima Charles, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in OncologyDawn Provenzale, Samir Gupta, Dennis J Ahnen, et al.
JCO Precision Oncology|June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1IShivaani Kummar, Zihe Song, Kim A Reiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
JCO Precision Oncology|September 21, 2020
Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary CancersKara N Maxwell, Brandon M Wenz, Abha Kulkarni, et al.
Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.
JCO Precision Oncology|July 29, 2021
Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer RiskGregory E Idos, Allison W Kurian, Charité Ricker, et al.
Pageof 19